The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 03, 2017
Filed:
Jul. 15, 2015
Applicant:
Qu Biologics Inc., Vancouver, CA;
Inventor:
Harold David Gunn, Vancouver, CA;
Assignee:
Qu Biologics Inc., Vancouver, CA;
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/085 (2006.01); A61K 39/09 (2006.01); A61K 39/235 (2006.01); A61K 31/405 (2006.01); A61K 31/635 (2006.01); A61K 31/192 (2006.01); A61K 39/108 (2006.01); A61K 39/112 (2006.01); A61K 39/104 (2006.01); A61K 33/24 (2006.01); A61K 39/02 (2006.01); A61K 39/102 (2006.01); A61K 39/145 (2006.01); A61K 39/155 (2006.01); G01N 33/50 (2006.01); C12R 1/445 (2006.01);
U.S. Cl.
CPC ...
A61K 39/235 (2013.01); A61K 31/192 (2013.01); A61K 31/405 (2013.01); A61K 31/635 (2013.01); A61K 33/24 (2013.01); A61K 39/0011 (2013.01); A61K 39/0241 (2013.01); A61K 39/0258 (2013.01); A61K 39/0266 (2013.01); A61K 39/0275 (2013.01); A61K 39/085 (2013.01); A61K 39/092 (2013.01); A61K 39/102 (2013.01); A61K 39/1045 (2013.01); A61K 39/145 (2013.01); A61K 39/155 (2013.01); G01N 33/5055 (2013.01); G01N 33/5088 (2013.01); A61K 2039/521 (2013.01); A61K 2039/522 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/545 (2013.01); A61K 2039/575 (2013.01); A61K 2039/585 (2013.01); A61K 2039/70 (2013.01); C12N 2710/10032 (2013.01); C12N 2760/16032 (2013.01); C12N 2760/18532 (2013.01); C12N 2760/18632 (2013.01); C12R 1/445 (2013.01);
Abstract
The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.